Home Cart Sign in  
Chemical Structure| 293753-05-6 Chemical Structure| 293753-05-6

Structure of SR3335
CAS No.: 293753-05-6

Chemical Structure| 293753-05-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SR3335 can selectively bind to RORα and competitively inhibit the binding of 25-hydroxycholesterol to the ligand binding domain with Ki of 220 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SR3335

CAS No. :293753-05-6
Formula : C13H9F6NO3S2
M.W : 405.34
SMILES Code : O=S(C1=CC=CS1)(NC2=CC=C(C(C(F)(F)F)(O)C(F)(F)F)C=C2)=O
MDL No. :MFCD02724814
InChI Key :LZWUNZRMANFRAO-UHFFFAOYSA-N
Pubchem ID :2360837

Safety of SR3335

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human nucleus pulposus cells 1 µM 24 hours SR3335 treatment reversed the trend of increased apoptosis in NP cells induced by TNF-α treatment and upregulated the expression of type II collagen and aggrecan while downregulating MMP13 and ADAMTS4. Mediators Inflamm. 2021 Jul 28;2021:9954909
HepG2 cells 5 µM 24 hours To evaluate the inhibitory effect of SR3335 on endogenous RORα target gene expression, results showed that SR3335 significantly suppressed G6Pase and PEPCK mRNA expression. ACS Chem Biol. 2011 Mar 18;6(3):218-22
HEK293 cells 5 µM 24 hours To evaluate the inhibitory effect of SR3335 on RORα transcriptional activity, results showed that SR3335 significantly suppressed transcription driven by the G6Pase promoter. ACS Chem Biol. 2011 Mar 18;6(3):218-22
Chick bursal B lymphocytes 5 µM 30 min pretreatment Inhibited B-lymphocyte apoptosis, decreased IL-6, TNF-α, IFN-γ and ROS production, down-regulated RORα/RORγ mRNA level and p-iκB, p-p65 protein expression, whereas improved IL-10 level and Nrf2, HO-1 protein expression. Antioxidants (Basel). 2022 Apr 8;11(4):748.
Chick thymic lymphocytes 5 µM 30 min pretreatment followed by 44 hours culture SR3335 enhanced the stimulative effect of melatonin on p-AKT expression and increased the expression levels of β-catenin and CyclinD1 Poult Sci. 2024 Dec;103(12):104507
B lymphocytes 5 µM 30 minutes To investigate the effect of SR3335 on GL-induced B lymphocyte proliferation. Results showed that pretreatment with SR3335 increased B lymphocyte proliferation by 7.88%. Poult Sci. 2020 Sep;99(9):4294-4302
T lymphocytes 5 µM 30 minutes To investigate the effect of SR3335 on GL-induced T lymphocyte proliferation. Results showed that pretreatment with SR3335 increased T lymphocyte proliferation by 12.48%. Poult Sci. 2020 Sep;99(9):4294-4302
Human chondrocytes 0.5-1 µM 48 hours SR3335 treatment upregulated the expression of COL2A1 and SOX9 while suppressing ADAMTS4 and MMP13, indicating it promotes extracellular matrix synthesis and inhibits degradation in chondrocytes. Cell Death Dis. 2021 Sep 28;12(10):886.
Primary neonatal cardiac fibroblasts 20 µM 48 hours SR3335 promoted cell injury and proliferation, enhanced collagen synthesis, facilitated oxidative stress and necroptosis in cardiac fibroblasts with high glucose stimulation Front Pharmacol. 2025 Jan 30;16:1539690
Chicken thymic lymphocytes 5 µM 48 hours SR3335 (ROR α antagonist) attenuated the melatonin-induced increase in Bcl-2 protein levels and decrease in Bax protein levels. Poult Sci. 2024 Feb;103(2):103331
Human CD4+ T cells 5 µM 6 days To evaluate the effect of SR3335 on IL-17A expression in human CD4+ T cells under TH17-polarizing conditions. Results showed that SR3335 dose-dependently inhibited IL-17A expression. Nat Commun. 2021 Jan 4;12(1):76
Mouse CD4+ T cells 5 µM 96 hours To evaluate the effect of SR3335 on IL-17A expression in mouse CD4+ T cells under TH17-polarizing conditions. Results showed that SR3335 dose-dependently suppressed IL-17A expression without affecting cell viability. Nat Commun. 2021 Jan 4;12(1):76

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice RORα-knockout (sg/sg) mice Intraperitoneal injection 10 mg/kg 4 consecutive days SR3335 reduced TG content in the liver and plasma, and increased plasma glycerol concentration, suggesting an activation of adipose lipolysis. Sci Rep. 2025 Mar 26;15(1):10464
Sprague-Dawley rats Needle puncture-induced intervertebral disc degeneration model Intraperitoneal injection 10 mg/kg/day Every 3 days for 4 weeks SR3335 treatment restored the expression of aggrecan and reduced the expression of the apoptosis marker cleaved caspase 3. Mediators Inflamm. 2021 Jul 28;2021:9954909
Mice LPS-induced endotoxic shock model Intraperitoneal injection 15 mg/kg Once daily for 7 days To evaluate the protective effect of SR3335 on LPS-induced endotoxic shock, results showed that SR3335 significantly improved survival and clinical scores in mice Front Immunol. 2021 Mar 9;12:647329
C57BL/6 mice Diet-induced obesity model Intraperitoneal injection 15 mg/kg Twice daily for 6 days To evaluate the inhibitory effect of SR3335 on gluconeogenesis, results showed that SR3335 significantly reduced plasma glucose levels, indicating its suppression of gluconeogenesis. ACS Chem Biol. 2011 Mar 18;6(3):218-22
Mice Experimental autoimmune encephalomyelitis (EAE) model Intraperitoneal injection 30 mg/kg Twice daily, for the duration of the experiment To evaluate the therapeutic effect of SR3335 in the EAE model. Results showed that SR3335 significantly reduced the relapse rate and severity of relapse, and inhibited inflammatory cell infiltration in the CNS. Nat Commun. 2021 Jan 4;12(1):76

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.34mL

2.47mL

1.23mL

24.67mL

4.93mL

2.47mL

References

 

Historical Records

Categories